[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602407":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":29,"centralContacts":33,"locations":42,"responsibleParty":136,"collaborators":28,"id":138,"slug":139,"hasResults":140,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":28,"eligibilityCriteria":144,"healthyVolunteers":140,"sex":145,"minAge":146,"maxAge":28,"enrollmentInfo":147,"targetDuration":28,"studyType":150,"phases":151,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":45,"whyStopped":28,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},{"fullName":5,"class":6},"Exelixis","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose-escalation Cohorts","EXPERIMENTAL","Participants will receive escalating doses of XB371 every 3 weeks of a 21-day cycle (alternate schedules may be evaluated) until meeting the criteria for treatment discontinuation.",[13],"Drug: XB371",{"label":15,"type":10,"description":16,"interventionNames":17},"Dose-expansion Cohorts: Part A","Participants with Tumor Type 1 (tumor type will be selected based on available data) will be randomized to receive XB371 at one of two recommended dose levels (recommended dose \\[RD\\]-1 or RD-2) every 3 weeks of a 21-day cycle (alternate schedules may be evaluated) until meeting the criteria for treatment discontinuation.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Dose-expansion Cohorts: Part B","Participants with Tumor Type 2 (tumor type will be selected based on available data) will receive XB371 at the recommended dose level every 3 weeks of a 21-day cycle (alternate schedules may be evaluated) until meeting the criteria for treatment discontinuation.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","XB371","Intravenous (IV) infusion.",[9,15,19],null,[30],{"name":31,"affiliation":5,"role":32},"Medical Director","STUDY_DIRECTOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":28,"email":38},"Exelixis Clinical Trials","CONTACT","1-888-EXELIXIS (888-393-5494)","druginfo@exelixis.com",{"name":40,"role":36,"phone":41,"phoneExt":28,"email":28},"Backup or International","1-650-837-7400",[43,57,67,77,87,97,107,117,127],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":28},"Exelixis Clinical Site #5","RECRUITING","Rogers","Arkansas","72758","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-94.11854,36.33202,{"lat":55,"lon":54},{"facility":58,"status":45,"city":59,"state":60,"zip":61,"country":49,"countryCode":50,"cosmosGeoPoint":62,"geoPoint":66,"contacts":28},"Exelixis Clinical Site #9","Los Angeles","California","90033",{"type":52,"coordinates":63},[64,65],-118.24368,34.05223,{"lat":65,"lon":64},{"facility":68,"status":45,"city":69,"state":70,"zip":71,"country":49,"countryCode":50,"cosmosGeoPoint":72,"geoPoint":76,"contacts":28},"Exelixis Clinical Site #6","Washington D.C.","District of Columbia","20057",{"type":52,"coordinates":73},[74,75],-77.03637,38.89511,{"lat":75,"lon":74},{"facility":78,"status":45,"city":79,"state":80,"zip":81,"country":49,"countryCode":50,"cosmosGeoPoint":82,"geoPoint":86,"contacts":28},"Exelixis Clinical Site #4","Orlando","Florida","32827",{"type":52,"coordinates":83},[84,85],-81.37924,28.53834,{"lat":85,"lon":84},{"facility":88,"status":45,"city":89,"state":90,"zip":91,"country":49,"countryCode":50,"cosmosGeoPoint":92,"geoPoint":96,"contacts":28},"Exelixis Clinical Site #3","Grand Rapids","Michigan","49546",{"type":52,"coordinates":93},[94,95],-85.66809,42.96336,{"lat":95,"lon":94},{"facility":98,"status":45,"city":99,"state":100,"zip":101,"country":49,"countryCode":50,"cosmosGeoPoint":102,"geoPoint":106,"contacts":28},"Exelixis Clinical Site #7","New Brunswick","New Jersey","08901",{"type":52,"coordinates":103},[104,105],-74.45182,40.48622,{"lat":105,"lon":104},{"facility":108,"status":45,"city":109,"state":110,"zip":111,"country":49,"countryCode":50,"cosmosGeoPoint":112,"geoPoint":116,"contacts":28},"Exelixis Clinical Site #2","Huntersville","North Carolina","28078",{"type":52,"coordinates":113},[114,115],-80.84285,35.41069,{"lat":115,"lon":114},{"facility":118,"status":45,"city":119,"state":120,"zip":121,"country":49,"countryCode":50,"cosmosGeoPoint":122,"geoPoint":126,"contacts":28},"Exelixis Clinical Site #8","Houston","Texas","77030",{"type":52,"coordinates":123},[124,125],-95.36327,29.76328,{"lat":125,"lon":124},{"facility":128,"status":45,"city":129,"state":120,"zip":130,"country":49,"countryCode":50,"cosmosGeoPoint":131,"geoPoint":135,"contacts":28},"Exelixis Clinical Site #1","San Antonio","78229",{"type":52,"coordinates":132},[133,134],-98.49363,29.42412,{"lat":134,"lon":133},{"type":137,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100602407","phase-1-a-study-of-xb371-administered-in-participants-with-locally-advanced-or-metastatic-solid-tumors-100602407",false,"NCT07123103","A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors","A Dose Escalation and Expansion Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Minimum life expectancy of ≥ 12 weeks.\n* Recurrent locally advanced or metastatic solid tumors.\n* Adequate end organ and bone marrow function.\n\nKey Exclusion Criteria:\n\n* Primary brain tumors or known active brain metastases, leptomeningeal, or cranial epidural disease.\n* History of interstitial lung disease (ILD) of any grade or history of organizing pneumonia.\n* Has acute ocular infection, acute or chronic ulcerative\u002Fcicatricial condition of conjunctiva or cornea.\n* Known history of immunodeficiency virus (HIV) unless specific criteria are met.\n* Active infection with hepatitis C virus (HCV) defined as positive for HCV antibody.\n* Major surgery within 4 weeks before the first dose of study treatment.\n* Received radiation therapy within 2 weeks before the first dose of study treatment.\n* Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study treatment.\n\nNOTE: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":148,"type":149},150,"ESTIMATED","INTERVENTIONAL",[152],"PHASE1","The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.",[155],"Solid Tumors",[157,158],"Advanced Solid Tumors","Metastatic Solid Tumors","2026-02-13",{"date":161,"type":162},"2026-02-17","ACTUAL",{"date":164,"type":162},"2025-08-18",{"date":166,"type":149},"2028-02",{"name":5,"class":6},9]